featured
2020 Top Stories in Neurology: Rituximab Treatment for New-Onset Generalized Myasthenia Gravis: Promising Effects for Long-Term Remission
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nature Rev Neurol. 2019;15(2):113-124.
- Dalakas MC. Progress in the therapy of myasthenia gravis: getting closer to effective targeted Immunotherapies. Curr Opin Neurol. 2020,33(5):545-552.
- Brauner S, Eriksson-Dufva A, Albert Hietala M, et al. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol. 2020;77(8):974-981.
- Mariapaola Marino M, Basile U, Spagni G, et al. Long-lasting rituximab-induced reduction of specific—but not total—IgG4 in MuSK-positive myasthenia gravis. Front Immunol. 2020;11:613.
Disclosure statements are available on the authors' profiles: